Zura Bio updates 2026 outlook and trials

Zura Bio Limited furnished a new corporate presentation and issued a press release tied to its business outlook.

Rhea-AI Filing Summary

Zura Bio Limited furnished a new corporate presentation and issued a press release tied to its business outlook. The presentation, dated January 12, 2026, may be used at conferences and investor meetings and is available as Exhibit 99.1 and through the company’s investor website.

The press release, filed as Exhibit 99.2, discusses corporate and clinical trial updates and the company’s outlook for 2026, including its cash runway and expected topline data timelines for two ongoing Phase 2 studies of tibulizumab in hidradenitis suppurativa and systemic sclerosis. Both exhibits are referenced in this current report.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Zura Bio (ZURA) report in its latest 8-K filing?

Zura Bio Limited reported that it furnished an updated corporate presentation and issued a press release covering corporate and clinical trial updates and its 2026 outlook.

What is included in Zura Bio’s updated corporate presentation?

The updated corporate presentation, dated January 12, 2026 and filed as Exhibit 99.1, is intended for use at upcoming conferences and investor meetings and is also accessible via the company’s investor website.

What topics does Zura Bio’s new press release cover?

The press release, filed as Exhibit 99.2, provides corporate and clinical trial updates and discusses Zura Bio’s outlook for 2026, including its cash runway and expected topline data readout timelines.

Which clinical programs are highlighted in the Zura Bio press release?

The press release highlights two ongoing Phase 2 clinical studies of tibulizumab, Zura Bio’s lead dual-pathway antibody, in hidradenitis suppurativa and systemic sclerosis.

How can investors access Zura Bio’s updated corporate presentation?

Investors can access the corporate presentation furnished as Exhibit 99.1 to the report and through the “News & Events” section of Zura Bio’s investor website at investors.zurabio.com.

Is the information in Zura Bio’s corporate presentation considered filed with the SEC?

No. The company states that information under Item 7.01, including Exhibit 99.1, is furnished, not filed, and is not subject to certain liability provisions or automatically incorporated into other SEC filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 06:45 AM Learn about SEC filing dates

false 0001855644 0001855644 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

Warrants [Member]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

January 12, 2026

Date of Report (Date of earliest event reported)

Zura Bio Limited

(Exact name of registrant as specified in its charter)

Cayman Islands		001-40598		98-1725736
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1489 W. Warm Springs Rd. #110

Henderson, NV 89014

 (Address of principal executive offices,
including zip code)

(702) 825-9872

 (Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Ordinary Shares, par value $0.0001 per share		ZURA		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure.

On January 12, 2026, Zura Bio Limited (the “Company”) provided an updated corporate presentation that may be used in connection with upcoming presentations at conferences and investor meetings. The full text of the Company’s corporate presentation is furnished as Exhibit 99.1 hereto, and is incorporated herein by reference, and may also be accessed through the “News & Events” section of the Company’s website at investors.zurabio.com.

The information furnished under this Item 7.01 (including Exhibit 99.1), shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On January 12, 2026, the Company issued a press release announcing certain corporate and clinical trial updates and its outlook for 2026, including updates on the Company’s cash runway and expected topline data readout timelines for its two ongoing Phase 2 clinical studies of tibulizumab, the Company’s lead dual-pathway antibody, in hidradenitis suppurativa and systemic sclerosis.

A copy of the press release is filed as Exhibit 99.2 hereto and is incorporated herein by reference. 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1	Corporate Presentation, dated January 12, 2026
99.2	Press Release, dated January 12, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ZURA BIO LIMITED
Date: January 12, 2026	By:	/s/ Kim Davis
		Kim Davis
		Interim Chief Executive Officer, Chief Operating Officer, Chief Legal Officer and Corporate Secretary